Genevieve Plu-Bureau

Summary

Country: France

Publications

  1. doi request reprint Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis
    Zeina Chakhtoura
    Department of Gynecology and Endocrinology, Hopital Hotel Dieu, Assistance Publique Hopitaux de Paris, Paris Descartes University, 75004 Paris, France
    J Clin Endocrinol Metab 96:1169-74. 2011
  2. ncbi request reprint [A French exception. Transdermal postmenopausal hormone therapy]
    Genevieve Plu-Bureau
    Unité de gynécologie endocrinienne, Hopital Hotel Dieu, AP HP, 75004 Paris
    Rev Prat 60:1122-3, 1125-30. 2010
  3. ncbi request reprint Cyclical mastalgia and breast cancer risk: results of a French cohort study
    Genevieve Plu-Bureau
    Department of Reproductive Endocrinology, Hospital Necker, Paris, France
    Cancer Epidemiol Biomarkers Prev 15:1229-31. 2006
  4. doi request reprint [Hormonal contraception and risk of venous thromboembolism: When to ask for an assessment of hemostasis? Which parameters?]
    G Plu-Bureau
    Unité de gynécologie endocrinienne, Hopital Hotel Dieu, Assistance Publique des Hopitaux de Paris AP HP, Universite Paris Descartes, 1, Place du Parvis Notre Dame, 75181 Paris Cedex 04, France
    Gynecol Obstet Fertil 36:448-54. 2008
  5. ncbi request reprint Influence of hormonal control on LH pulsatility and secretion in women with classical congenital adrenal hyperplasia
    Anne Bachelot
    AP HP, Department of Endocrinology and Reproductive Medicine, Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Pitié Salpêtrière Hospital Groupe Hospitalier Pitié Salpêtrière, Universite Pierre et Marie Curie, Site Pitié, 47 83 boulevard de l Hopital, 75013 Paris, France
    Eur J Endocrinol 167:499-505. 2012
  6. doi request reprint Hormonal contraceptives and arterial disease: an epidemiological update
    Genevieve Plu-Bureau
    Department of Gynecology and Endocrinology, Hôpital Universitaire Paris Centre, Paris Descartes University, Paris, France
    Best Pract Res Clin Endocrinol Metab 27:35-45. 2013
  7. ncbi request reprint Death-associated protein kinase loss of expression is a new marker for breast cancer prognosis
    Delphine Lévy
    Unité de gynécologie endocrinienne, Hopital Hotel Dieu, Paris, France
    Clin Cancer Res 10:3124-30. 2004
  8. doi request reprint Progestogen-only contraceptives and the risk of stroke: a meta-analysis
    Zeina Chakhtoura
    Department of Gynecology and Endocrinology, Hotel Dieu Hospital, AP HP, Paris Descartes University, Paris, France
    Stroke 40:1059-62. 2009
  9. pmc Postmenopausal Hormone Therapy and Risk of Stroke: Impact of the Route of Estrogen Administration and Type of Progestogen
    Marianne Canonico
    From the Université Paris Saclay, Univ Paris Sud, UVSQ, Centre de Recheche en Epidémiologie et Santé des Populations, Inserm UMRS1018, Villejuif, France M C, E O, A S M, A E, P Y S Institut de veille sanitaire InVS, Département des Maladies Chroniques et des, Traumatismes, F 94415 Saint Maurice, France L C APHP, Hôpitaux Paris Centre, Unité de gynécologie endocrinienne, Paris, 75014, France et Université Paris Descartes G P B Université Paris Saclay, Univ Paris Sud, UVSQ, Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases, INSERM UMRS1181, Villejuif, France P T B and Institut Pasteur, Paris, France P T B
    Stroke 47:1734-41. 2016
  10. doi request reprint Epidemiology of hormonal contraceptives-related venous thromboembolism
    Justine Hugon-Rodin
    Department of Gynecology and EndocrinologyHôpitaux Universitaires Paris Centre, Paris Descartes University, Paris, France
    Eur J Endocrinol 171:R221-30. 2014

Collaborators

Detail Information

Publications25

  1. doi request reprint Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis
    Zeina Chakhtoura
    Department of Gynecology and Endocrinology, Hopital Hotel Dieu, Assistance Publique Hopitaux de Paris, Paris Descartes University, 75004 Paris, France
    J Clin Endocrinol Metab 96:1169-74. 2011
    ..While progestogen-only contraceptives (POC) are commonly used worldwide, their impact on cardiovascular diseases is poorly investigated and remains unclear...
  2. ncbi request reprint [A French exception. Transdermal postmenopausal hormone therapy]
    Genevieve Plu-Bureau
    Unité de gynécologie endocrinienne, Hopital Hotel Dieu, AP HP, 75004 Paris
    Rev Prat 60:1122-3, 1125-30. 2010
    ..These data are fundamental to assess the short-term risk-benefit balance that appears on the current available data favorable to the transdermal route of administration...
  3. ncbi request reprint Cyclical mastalgia and breast cancer risk: results of a French cohort study
    Genevieve Plu-Bureau
    Department of Reproductive Endocrinology, Hospital Necker, Paris, France
    Cancer Epidemiol Biomarkers Prev 15:1229-31. 2006
    ..It might be a confounding factor when assessing the effects of hormonal treatments on breast cancer risk such as hormonal replacement therapy or oral contraceptives...
  4. doi request reprint [Hormonal contraception and risk of venous thromboembolism: When to ask for an assessment of hemostasis? Which parameters?]
    G Plu-Bureau
    Unité de gynécologie endocrinienne, Hopital Hotel Dieu, Assistance Publique des Hopitaux de Paris AP HP, Universite Paris Descartes, 1, Place du Parvis Notre Dame, 75181 Paris Cedex 04, France
    Gynecol Obstet Fertil 36:448-54. 2008
    ..On the other hand, this biological research is not systematically recommended before any prescription of hormonal contraception in patients having neither previous personal nor family history of venous thrombosis...
  5. ncbi request reprint Influence of hormonal control on LH pulsatility and secretion in women with classical congenital adrenal hyperplasia
    Anne Bachelot
    AP HP, Department of Endocrinology and Reproductive Medicine, Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Pitié Salpêtrière Hospital Groupe Hospitalier Pitié Salpêtrière, Universite Pierre et Marie Curie, Site Pitié, 47 83 boulevard de l Hopital, 75013 Paris, France
    Eur J Endocrinol 167:499-505. 2012
    ..Our aim was to evaluate the gonadotropic axis and LH pulsatility patterns and to determine factor(s) that could account for the potential abnormality of LH pulsatility...
  6. doi request reprint Hormonal contraceptives and arterial disease: an epidemiological update
    Genevieve Plu-Bureau
    Department of Gynecology and Endocrinology, Hôpital Universitaire Paris Centre, Paris Descartes University, Paris, France
    Best Pract Res Clin Endocrinol Metab 27:35-45. 2013
    ..23 for MI risk and 0.99 for ischemic stroke). In conclusion, newer generation formulations of COCs, as well as the non-oral hormonal contraceptive, do not seem to be safer than second generation hormonal contraceptives...
  7. ncbi request reprint Death-associated protein kinase loss of expression is a new marker for breast cancer prognosis
    Delphine Lévy
    Unité de gynécologie endocrinienne, Hopital Hotel Dieu, Paris, France
    Clin Cancer Res 10:3124-30. 2004
    ..We analyzed the level of DAP-kinase expression in breast cancer specimens and its correlation with survival...
  8. doi request reprint Progestogen-only contraceptives and the risk of stroke: a meta-analysis
    Zeina Chakhtoura
    Department of Gynecology and Endocrinology, Hotel Dieu Hospital, AP HP, Paris Descartes University, Paris, France
    Stroke 40:1059-62. 2009
    ..The association between combined oral contraceptives (OC) use and increased risk of stroke has been reported. While progestogen-only contraceptives (POC) are commonly used worldwide, their impact on cardiovascular disease remains unclear...
  9. pmc Postmenopausal Hormone Therapy and Risk of Stroke: Impact of the Route of Estrogen Administration and Type of Progestogen
    Marianne Canonico
    From the Université Paris Saclay, Univ Paris Sud, UVSQ, Centre de Recheche en Epidémiologie et Santé des Populations, Inserm UMRS1018, Villejuif, France M C, E O, A S M, A E, P Y S Institut de veille sanitaire InVS, Département des Maladies Chroniques et des, Traumatismes, F 94415 Saint Maurice, France L C APHP, Hôpitaux Paris Centre, Unité de gynécologie endocrinienne, Paris, 75014, France et Université Paris Descartes G P B Université Paris Saclay, Univ Paris Sud, UVSQ, Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases, INSERM UMRS1181, Villejuif, France P T B and Institut Pasteur, Paris, France P T B
    Stroke 47:1734-41. 2016
    ..However, the differential association of oral and transdermal estrogens with stroke remains poorly investigated. Furthermore, there are no data regarding the impact of progestogens...
  10. doi request reprint Epidemiology of hormonal contraceptives-related venous thromboembolism
    Justine Hugon-Rodin
    Department of Gynecology and EndocrinologyHôpitaux Universitaires Paris Centre, Paris Descartes University, Paris, France
    Eur J Endocrinol 171:R221-30. 2014
    ..Further studies are needed to conclude on the combinations containing NGM or low doses of EE associated with GSD. ..
  11. doi request reprint Are we overestimating the stroke risk related to contraceptive pills?
    Anne Gompel
    Unité de gynécologie endocrinienne, Universite Paris Descartes, Hôpitaux Universitaires Paris Centre, APHP, Paris, France
    Curr Opin Neurol 27:29-34. 2014
    ..Given the benefits associated with combined hormonal contraceptives (COCs), it is important to properly evaluate their risks in order to provide a better benefit/risk balance to young women...
  12. doi request reprint Hormonal contraceptives and venous thromboembolism: an epidemiological update
    Genevieve Plu-Bureau
    Department of Gynecology and Endocrinology, Hôpital Universitaires Paris Centre, Paris Descartes University, Paris, France
    Best Pract Res Clin Endocrinol Metab 27:25-34. 2013
    ..In conclusion, newer generation formulations of hormonal contraceptives, as well as the non-oral hormonal contraceptive, seem to be more thrombogenic than second generation hormonal contraceptives...
  13. doi request reprint Management of granulomatous mastitis: a series of 14 patients
    Justine Hugon-Rodin
    Unité de gynécologie endocrinienne, Universite Paris Descartes, APHP, Hotel Dieu, 1 Place du Parvis Notre Dame, Paris Cedex 4, France
    Gynecol Endocrinol 28:921-4. 2012
    ..The duration and number of relapses are unpredictable, and the roles of surgery and corticosteroids remain controversial...
  14. ncbi request reprint Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study
    Gregoire Le Gal
    Unit 258, Institut National de la Sante et de la Recherche Medicale, Paris, France
    Atherosclerosis 166:163-70. 2003
    ..Information on the impact of hormone replacement therapy (HRT) on carotid atherosclerosis is limited. Moreover, transdermal estrogens have not been investigated...
  15. doi request reprint Catamenial pneumothorax and endometriosis-related pneumothorax: clinical features and risk factors
    Christine Rousset-Jablonski
    Department of Gynecological Endocrinology, Universite Paris Descartes, Assistance Publique Hopitaux de Paris, Hopital Hotel Dieu, 75181 Paris cedex 4, France
    Hum Reprod 26:2322-9. 2011
    ..The purpose of this study is to increase the diagnostic accuracy for these conditions in patients with spontaneous pneumothorax and to identify their risk factors...
  16. ncbi request reprint Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
    Anne Bachelot
    Department of Endocrinology and Reproductive Medicine, Necker Hospital, AP HP, Paris V University, Paris, France
    Horm Res 67:268-76. 2007
    ..We evaluated the long-term outcome and the impact of chronic glucocorticoid replacement in these patients...
  17. ncbi request reprint Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone
    Meyer Michel Samama
    Hemostasis and Thrombosis Unit, Hotel Dieu Hospital, Paris, France
    Br J Haematol 123:327-34. 2003
    ..In women with the FII mutation alone, the low risk may not justify prophylaxis in the absence of previous VTE. In post partum, prophylaxis is indicated in all cases...
  18. pmc The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression
    Sandra Dupouy
    INSERM UPMC CDR Saint Antoine EQ 5, Hopital Saint Antoine, Paris, France
    PLoS ONE 4:e4223. 2009
    ..In breast cancer cells, functionally expressed NT1 receptor coordinates a series of transforming functions including cellular migration and invasion...
  19. doi request reprint Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor
    Meyer Michel Samama
    Hotel Dieu University Hospital, Paris, France 2Biomnis Laboratory, Ivry sur Seine, France
    Thromb Haemost 103:815-25. 2010
    ..Finally, all clotting and chromogenic assays showed a concentration-dependent effect induced by rivaroxaban...
  20. ncbi request reprint [Quantitative evaluation of the cardiovascular risk associated with hormone substitution therapy during menopause]
    P Y Scarabin
    , U 258, , Paris
    Arch Mal Coeur Vaiss 86:243-8. 1993
    ..Randomised clinical trials are needed to determine the effects of postmenopausal hormone replacement therapy on athero-thrombotic disease...
  21. pmc Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors
    Roman L Bogorad
    Institut National de la Santé et de la Recherche Médicale U845, Equipe PRL, GH et Tumeurs, Centre de Recherche Croissance et Signalisation, F 75015 Paris, France
    Proc Natl Acad Sci U S A 105:14533-8. 2008
    ..Hallmarks of constitutive activity were all reversed by a specific PrlR antagonist, which opens potential therapeutic approaches for MFA, or any other disease that could be associated with this mutation in future...
  22. doi request reprint Insulin resistance, obesity and breast cancer risk
    C Pichard
    Unité de gynécologie endocrinienne, Hotel Dieu, APHP, Universite Paris 5, 1 Place du Parvis Notre Dame, Paris, France
    Maturitas 60:19-30. 2008
    ..This observation should be an encouragement for women since loss of weight may be an effective strategy for breast cancer risk reduction...
  23. ncbi request reprint [Could treatments with beta-blockers be associated with a reduction in cancer risk?]
    M Algazi
    Service de cardiologie et médecine interne, Hôpital Privé des Diaconesses, 18, rue du Sergent Bauchat, 75012 Paris
    Rev Epidemiol Sante Publique 52:53-65. 2004
    ..The relationship between the use of anti-hypertensive drugs and cancer risk remains controversial. The main objective of this study was to assess the potential effect of beta-blocker use on cancer risk...
  24. ncbi request reprint Breast diseases in adolescents
    C Duflos
    Service Endocrinologie Médecine de la Reproduction, Unité de Gynécologie Pédiatrique, Hopital Necker, Paris, France
    Endocr Dev 7:183-96. 2004
  25. ncbi request reprint [It is not advisable to prescribe hormonal replacement therapy to a woman with proliferative mastopathy with atypia]
    G Plu-Bureau
    Hopital Necker, Service Endocrinologie Médecine de la Reproduction, 149, rue de Sevres, 75015 Paris, France
    Gynecol Obstet Fertil 30:335-9. 2002